Boris Minev

Company: Calidi Biotherapeutics Inc.

Job title: President, Medical & Scientific Affairs

Seminars:

Optimized Cell-Based Delivery & Potentiation of Oncolytic Virotherapies 9:30 am

The novel Calidi’s platform leverages allogeneic stem cells, combined with an oncolytic virus payload, which prevents the viral elimination by the patient’s immune system, and facilitates initial viral amplification and expansion at the tumor sites Calidi’s final product contains not only stem cells loaded with viral particles, but also immune modulatory cytokines produced by the…Read more

day: Day Two

Fireside Chat: Navigating the Regulatory Landscape: Considerations for Oncolytic Viruses 12:00 pm

Development of guidelines and requirements for pre-clinical safety and toxicity studies specific to oncolytic viruses in the CMC field Addressing translational challenges when transitioning from animal models to human patients Establishing effective collaboration with regulatory authorities to ensure successful initiation of clinical trials Guidance for determining the distribution of each transgene in toxicity studies for…Read more

day: Pre-Conference Day

Investor Panel Discussion & Q&A: Bridging the Gap Between Pharma, Biotech & Investors 12:00 pm

This panel discussion will bring together experts from the investment community, pharma, and biotech sectors to facilitate the growth and development of the field. This panel will provide a platform for these stakeholders to connect, share perspectives, and explore potential partnerships. Take part in this deep-dive panel discussion and hear from the leading minds as…Read more

day: Day One